Complete financial analysis of Hisamitsu Pharmaceutical Co., Inc. (4530.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hisamitsu Pharmaceutical Co., Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Mahamaya Steel Industries Limited (MAHASTEEL.NS) Income Statement Analysis – Financial Results
- Oaktree Acquisition Corp. II (OACB) Income Statement Analysis – Financial Results
- Mila Resources Plc (MILA.L) Income Statement Analysis – Financial Results
- Frauenthal Holding AG (FKA.VI) Income Statement Analysis – Financial Results
- Reinsurance Group of America, Incorporated (RGA) Income Statement Analysis – Financial Results
Hisamitsu Pharmaceutical Co., Inc. (4530.T)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hisamitsu.co.jp
About Hisamitsu Pharmaceutical Co., Inc.
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 141.71B | 128.33B | 120.19B | 114.51B | 140.99B | 143.41B | 147.87B | 145.93B | 161.85B | 156.74B | 150.64B | 142.77B | 137.79B | 137.18B | 129.83B | 124.66B | 119.06B | 109.79B | 102.67B | 83.55B |
| Cost of Revenue | 62.74B | 55.63B | 50.13B | 45.34B | 53.39B | 54.73B | 55.69B | 53.16B | 58.32B | 57.06B | 55.47B | 51.66B | 46.79B | 47.70B | 42.66B | 39.88B | 36.10B | 32.91B | 29.84B | 24.72B |
| Gross Profit | 78.97B | 72.70B | 70.07B | 69.17B | 87.60B | 88.68B | 92.18B | 92.77B | 103.53B | 99.68B | 95.16B | 91.11B | 91.01B | 89.49B | 87.18B | 84.77B | 82.96B | 76.89B | 72.83B | 58.82B |
| Gross Profit Ratio | 55.73% | 56.65% | 58.30% | 60.41% | 62.13% | 61.84% | 62.34% | 63.57% | 63.97% | 63.59% | 63.18% | 63.82% | 66.05% | 65.23% | 67.14% | 68.00% | 69.68% | 70.03% | 70.93% | 70.41% |
| Research & Development | 8.61B | 9.79B | 10.61B | 10.77B | 10.50B | 13.03B | 15.08B | 14.38B | 14.97B | 13.72B | 13.92B | 12.66B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 25.29B | 23.22B | 20.58B | 20.20B | 22.87B | 24.17B | 23.87B | 25.07B | 29.42B | 30.30B | 31.36B | 84.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 31.90B | 28.10B | 29.54B | 27.53B | 31.50B | 29.20B | 26.90B | 26.09B | 30.36B | 34.19B | 29.88B | 28.33B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.19B | 51.31B | 50.12B | 47.74B | 54.37B | 53.37B | 50.76B | 51.16B | 59.77B | 64.49B | 61.24B | 52.41B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.00M | 197.00M | 417.00M | 414.00M | 330.00M | 382.00M | 1.01B | 482.00M | 355.00M | 573.00M | 509.00M | 470.00M | 740.00M | 702.00M | 814.00M | 879.00M | 828.00M | 779.00M | 1.11B | 276.00M |
| Operating Expenses | 65.80B | 61.10B | 60.73B | 58.50B | 64.88B | 66.40B | 65.84B | 66.46B | 75.80B | 79.15B | 76.04B | 65.79B | 65.07B | 61.29B | 58.59B | 52.24B | 53.89B | 50.75B | 50.05B | 37.32B |
| Cost & Expenses | 128.54B | 116.73B | 110.86B | 103.84B | 118.26B | 121.13B | 121.52B | 119.62B | 134.12B | 136.22B | 131.51B | 117.45B | 111.86B | 108.99B | 101.25B | 92.12B | 89.99B | 83.66B | 79.89B | 62.05B |
| Interest Income | 2.56B | 894.00M | 153.00M | 563.00M | 1.14B | 800.00M | 493.00M | 292.00M | 184.00M | 104.00M | 84.00M | 67.00M | 71.00M | 59.00M | 96.00M | 237.00M | 152.00M | 74.00M | 50.00M | 47.00M |
| Interest Expense | 18.00M | 15.00M | 20.00M | 10.00M | 19.00M | 19.00M | 32.00M | 39.00M | 32.00M | 34.00M | 34.00M | 38.00M | 92.00M | 125.00M | 108.00M | 19.00M | 21.00M | 41.00M | 41.00M | 34.00M |
| Depreciation & Amortization | 5.17B | 4.95B | 4.32B | 4.08B | 4.25B | 5.74B | 6.01B | 7.37B | 8.55B | 7.61B | 7.49B | 7.59B | 6.90B | 7.15B | 7.62B | 6.88B | 5.54B | 5.22B | 5.29B | 3.31B |
| EBITDA | 24.37B | 16.55B | 13.66B | 14.75B | 26.98B | 28.02B | 32.35B | 33.67B | 36.28B | 28.14B | 26.62B | 39.62B | 39.37B | 43.38B | 37.21B | 39.11B | 33.66B | 29.08B | 27.53B | 25.27B |
| EBITDA Ratio | 17.20% | 16.38% | 14.13% | 14.11% | 21.20% | 21.20% | 23.18% | 24.39% | 22.60% | 23.05% | 24.19% | 28.49% | 29.38% | 29.53% | 30.01% | 31.59% | 30.04% | 29.39% | 28.73% | 30.19% |
| Operating Income | 13.17B | 11.60B | 9.34B | 10.67B | 22.73B | 22.28B | 26.35B | 26.31B | 27.73B | 20.53B | 19.12B | 25.33B | 25.94B | 28.19B | 28.59B | 32.53B | 29.07B | 26.13B | 22.77B | 21.50B |
| Operating Income Ratio | 9.29% | 9.04% | 7.77% | 9.32% | 16.12% | 15.53% | 17.82% | 18.03% | 17.13% | 13.10% | 12.69% | 17.74% | 18.82% | 20.55% | 22.02% | 26.10% | 24.42% | 23.80% | 22.18% | 25.73% |
| Total Other Income/Expenses | 6.02B | 4.51B | 3.62B | 1.53B | 3.43B | 3.40B | 754.00M | 3.68B | 192.00M | 8.89B | 14.60B | 6.67B | 6.44B | 7.91B | 3.26B | -324.00M | 1.14B | -217.00M | 1.74B | 403.00M |
| Income Before Tax | 19.19B | 16.11B | 12.96B | 12.20B | 26.16B | 25.67B | 27.69B | 29.98B | 27.92B | 29.42B | 33.73B | 31.99B | 32.38B | 36.10B | 31.85B | 32.21B | 30.21B | 25.92B | 24.51B | 21.90B |
| Income Before Tax Ratio | 13.54% | 12.56% | 10.78% | 10.65% | 18.55% | 17.90% | 18.73% | 20.55% | 17.25% | 18.77% | 22.39% | 22.41% | 23.50% | 26.32% | 24.53% | 25.84% | 25.37% | 23.61% | 23.87% | 26.21% |
| Income Tax Expense | 4.75B | 3.99B | 3.09B | 2.76B | 7.24B | 6.29B | 8.37B | 9.44B | 9.99B | 10.43B | 12.17B | 13.41B | 13.76B | 14.98B | 13.28B | 13.02B | 11.48B | 10.06B | 10.00B | 8.86B |
| Net Income | 13.97B | 11.74B | 9.66B | 9.25B | 18.69B | 19.20B | 19.12B | 20.40B | 17.78B | 18.78B | 21.36B | 18.81B | 18.44B | 20.96B | 18.42B | 19.12B | 18.66B | 15.85B | 14.45B | 12.87B |
| Net Income Ratio | 9.86% | 9.15% | 8.04% | 8.08% | 13.26% | 13.39% | 12.93% | 13.98% | 10.99% | 11.98% | 14.18% | 13.17% | 13.38% | 15.28% | 14.19% | 15.34% | 15.68% | 14.43% | 14.07% | 15.41% |
| EPS | 181.61 | 148.00 | 118.92 | 113.21 | 227.58 | 230.08 | 228.35 | 241.27 | 208.81 | 219.28 | 249.30 | 219.56 | 215.09 | 241.80 | 210.78 | 215.61 | 210.45 | 178.40 | 159.75 | 141.30 |
| EPS Diluted | 181.41 | 147.87 | 118.84 | 113.10 | 227.30 | 229.86 | 228.35 | 241.15 | 208.76 | 219.28 | 249.30 | 219.56 | 215.09 | 241.80 | 210.78 | 215.61 | 210.45 | 178.40 | 159.75 | 141.30 |
| Weighted Avg Shares Out | 76.92M | 79.34M | 81.21M | 81.71M | 82.14M | 83.47M | 83.67M | 84.53M | 85.17M | 85.67M | 85.67M | 85.67M | 85.73M | 86.67M | 87.41M | 88.68M | 88.71M | 88.72M | 90.08M | 90.68M |
| Weighted Avg Shares Out (Dil) | 77.00M | 79.41M | 81.27M | 81.79M | 82.25M | 83.55M | 83.73M | 84.57M | 85.19M | 85.67M | 85.67M | 85.67M | 85.73M | 86.67M | 87.41M | 88.68M | 88.71M | 88.72M | 90.08M | 90.68M |
Source: https://incomestatements.info
Category: Stock Reports